-DOCSTART- -X- O
BACKGROUND -X- _ O
& -X- _ O
OBJECTIVES -X- _ O
: -X- _ O
Pre-clinical -X- _ O
toxicology -X- _ O
evaluation -X- _ O
of -X- _ O
biotechnology -X- _ O
products -X- _ O
is -X- _ O
achallenge -X- _ O
to -X- _ O
the -X- _ O
toxicologist. -X- _ O
The -X- _ O
present -X- _ O
investigation -X- _ O
is -X- _ O
an -X- _ O
attempt -X- _ O
to -X- _ O
evaluate -X- _ O
the -X- _ O
safety -X- _ O
profile -X- _ O
of -X- _ O
the -X- _ O
first -X- _ O
indigenously -X- _ O
developed -X- _ O
recombinant -X- _ B-Intervention
DNA -X- _ I-Intervention
anti-rabies -X- _ I-Intervention
vaccine -X- _ I-Intervention
[ -X- _ O
DRV -X- _ O
( -X- _ O
100 -X- _ O
μg -X- _ O
) -X- _ O
] -X- _ O
and -X- _ O
combination -X- _ B-Intervention
rabies -X- _ I-Intervention
vaccine -X- _ I-Intervention
[ -X- _ O
CRV -X- _ O
( -X- _ O
100 -X- _ O
μg -X- _ O
DRV -X- _ O
and -X- _ O
1.25 -X- _ O
IU -X- _ O
of -X- _ O
cell -X- _ O
culture-derived -X- _ O
inactivated -X- _ O
rabies -X- _ O
virus -X- _ O
vaccine -X- _ O
) -X- _ O
] -X- _ O
, -X- _ O
which -X- _ O
are -X- _ O
intended -X- _ O
for -X- _ O
clinical -X- _ O
use -X- _ O
by -X- _ O
intramuscular -X- _ B-Intervention
route -X- _ I-Intervention
in -X- _ O
Rhesus -X- _ B-Patient
monkeys -X- _ I-Patient
. -X- _ O

METHODS -X- _ O
: -X- _ O
As -X- _ O
per -X- _ O
the -X- _ O
regulatory -X- _ O
requirements -X- _ O
, -X- _ O
the -X- _ O
study -X- _ O
was -X- _ O
designed -X- _ O
for -X- _ O
acute -X- _ O
( -X- _ B-Intervention
single -X- _ I-Intervention
dose -X- _ I-Intervention
- -X- _ I-Intervention
14 -X- _ I-Intervention
days -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
sub-chronic -X- _ I-Intervention
( -X- _ I-Intervention
repeat -X- _ I-Intervention
dose -X- _ I-Intervention
- -X- _ I-Intervention
28 -X- _ I-Intervention
days -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
chronic -X- _ I-Intervention
( -X- _ I-Intervention
intended -X- _ I-Intervention
clinical -X- _ I-Intervention
dose -X- _ I-Intervention
- -X- _ I-Intervention
120 -X- _ I-Intervention
days -X- _ I-Intervention
) -X- _ I-Intervention
toxicity -X- _ I-Intervention
tests -X- _ I-Intervention
using -X- _ I-Intervention
three -X- _ I-Intervention
dose -X- _ I-Intervention
levels -X- _ I-Intervention
, -X- _ I-Intervention
viz. -X- _ I-Intervention
therapeutic -X- _ I-Intervention
, -X- _ I-Intervention
average -X- _ I-Intervention
( -X- _ I-Intervention
2x -X- _ I-Intervention
therapeutic -X- _ I-Intervention
dose -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
highest -X- _ I-Intervention
dose -X- _ I-Intervention
( -X- _ I-Intervention
10 -X- _ I-Intervention
x -X- _ I-Intervention
therapeutic -X- _ I-Intervention
dose -X- _ I-Intervention
) -X- _ I-Intervention
exposure -X- _ I-Intervention
in -X- _ O
monkeys. -X- _ B-Patient
The -X- _ O
selection -X- _ O
of -X- _ O
the -X- _ O
model -X- _ O
i.e. -X- _ O
monkey -X- _ O
was -X- _ O
based -X- _ O
on -X- _ O
affinity -X- _ O
and -X- _ O
rapid -X- _ O
higher -X- _ O
antibody -X- _ O
response -X- _ O
during -X- _ O
the -X- _ O
efficacy -X- _ O
studies. -X- _ O
An -X- _ O
attempt -X- _ O
was -X- _ O
made -X- _ O
to -X- _ O
evaluate -X- _ O
all -X- _ O
parameters -X- _ O
which -X- _ O
included -X- _ O
physical -X- _ O
, -X- _ O
physiological -X- _ O
, -X- _ O
clinical -X- _ O
, -X- _ O
haematological -X- _ O
and -X- _ O
histopathological -X- _ O
profiles -X- _ O
of -X- _ O
all -X- _ O
target -X- _ O
organs -X- _ O
, -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
Tiers -X- _ O
I -X- _ O
, -X- _ O
II -X- _ O
, -X- _ O
III -X- _ O
immunotoxicity -X- _ O
parameters -X- _ O
. -X- _ O

RESULTS -X- _ O
: -X- _ O
In -X- _ B-Outcome
acute -X- _ I-Outcome
toxicity -X- _ I-Outcome
there -X- _ I-Outcome
was -X- _ I-Outcome
no -X- _ I-Outcome
mortality -X- _ I-Outcome
in -X- _ I-Outcome
spite -X- _ I-Outcome
of -X- _ I-Outcome
exposing -X- _ I-Outcome
the -X- _ I-Outcome
monkeys -X- _ I-Outcome
to -X- _ I-Outcome
10XDRV. -X- _ I-Outcome
In -X- _ I-Outcome
sub -X- _ I-Outcome
chronic -X- _ I-Outcome
and -X- _ I-Outcome
chronic -X- _ I-Outcome
toxicity -X- _ I-Outcome
studies -X- _ I-Outcome
there -X- _ I-Outcome
were -X- _ I-Outcome
no -X- _ I-Outcome
abnormalities -X- _ I-Outcome
in -X- _ I-Outcome
physical -X- _ I-Outcome
, -X- _ I-Outcome
physiological -X- _ I-Outcome
, -X- _ I-Outcome
neurological -X- _ I-Outcome
, -X- _ I-Outcome
clinical -X- _ I-Outcome
parameters -X- _ I-Outcome
, -X- _ I-Outcome
after -X- _ I-Outcome
administration -X- _ I-Outcome
of -X- _ I-Outcome
test -X- _ I-Outcome
compound -X- _ I-Outcome
in -X- _ I-Outcome
intended -X- _ I-Outcome
and -X- _ I-Outcome
10 -X- _ I-Outcome
times -X- _ I-Outcome
of -X- _ I-Outcome
clinical -X- _ I-Outcome
dosage -X- _ I-Outcome
schedule -X- _ I-Outcome
of -X- _ I-Outcome
DRV -X- _ I-Outcome
and -X- _ I-Outcome
CRV -X- _ I-Outcome
under -X- _ I-Outcome
the -X- _ I-Outcome
experimental -X- _ I-Outcome
conditions. -X- _ I-Outcome
Clinical -X- _ I-Outcome
chemistry -X- _ I-Outcome
, -X- _ I-Outcome
haematology -X- _ I-Outcome
, -X- _ I-Outcome
organ -X- _ I-Outcome
weights -X- _ I-Outcome
and -X- _ I-Outcome
histopathology -X- _ I-Outcome
studies -X- _ I-Outcome
were -X- _ I-Outcome
essentially -X- _ I-Outcome
unremarkable -X- _ I-Outcome
except -X- _ I-Outcome
the -X- _ I-Outcome
presence -X- _ I-Outcome
of -X- _ I-Outcome
residual -X- _ I-Outcome
DNA -X- _ I-Outcome
in -X- _ I-Outcome
femtogram -X- _ I-Outcome
level -X- _ I-Outcome
at -X- _ I-Outcome
site -X- _ I-Outcome
of -X- _ I-Outcome
injection -X- _ I-Outcome
in -X- _ I-Outcome
animal -X- _ I-Outcome
which -X- _ I-Outcome
received -X- _ I-Outcome
10X -X- _ I-Outcome
DRV -X- _ I-Outcome
in -X- _ I-Outcome
chronic -X- _ I-Outcome
toxicity -X- _ I-Outcome
study. -X- _ I-Outcome
No -X- _ I-Outcome
Observational -X- _ I-Outcome
Adverse -X- _ I-Outcome
Effects -X- _ I-Outcome
Level -X- _ I-Outcome
( -X- _ I-Outcome
NOAEL -X- _ I-Outcome
) -X- _ I-Outcome
of -X- _ I-Outcome
DRV -X- _ I-Outcome
is -X- _ I-Outcome
1000 -X- _ I-Outcome
ug -X- _ I-Outcome
/ -X- _ I-Outcome
dose -X- _ I-Outcome
( -X- _ I-Outcome
10 -X- _ I-Outcome
times -X- _ I-Outcome
of -X- _ I-Outcome
therapeutic -X- _ I-Outcome
dose -X- _ I-Outcome
) -X- _ I-Outcome
if -X- _ I-Outcome
administered -X- _ I-Outcome
on -X- _ I-Outcome
0 -X- _ I-Outcome
, -X- _ I-Outcome
4 -X- _ I-Outcome
, -X- _ I-Outcome
7 -X- _ I-Outcome
, -X- _ I-Outcome
14 -X- _ I-Outcome
, -X- _ I-Outcome
28 -X- _ I-Outcome
( -X- _ I-Outcome
th -X- _ I-Outcome
) -X- _ I-Outcome
day -X- _ I-Outcome
. -X- _ O

INTERPRETATION -X- _ O
& -X- _ O
CONCLUSIONS -X- _ O
: -X- _ O
The -X- _ O
information -X- _ O
generated -X- _ O
by -X- _ O
this -X- _ O
study -X- _ O
not -X- _ O
only -X- _ O
draws -X- _ O
attention -X- _ O
to -X- _ O
the -X- _ O
need -X- _ O
for -X- _ O
national -X- _ O
and -X- _ O
international -X- _ O
regulatory -X- _ O
agencies -X- _ O
in -X- _ O
formulating -X- _ O
guidelines -X- _ O
for -X- _ O
pre-clinical -X- _ O
safety -X- _ O
evaluation -X- _ O
of -X- _ O
biotech -X- _ O
products -X- _ O
but -X- _ O
also -X- _ O
facilitates -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
biopharmaceuticals -X- _ O
as -X- _ O
safe -X- _ O
potential -X- _ O
therapeutic -X- _ O
agents -X- _ O
. -X- _ O

